Licensing

Concert Pharmaceuticals is looking to strategically partner with select pharmaceutical companies that are motivated to build substantial value through deuterated New Chemical Entities.

Please follow the links below to download licensing-related documents:

Concert Pharmaceuticals fact sheet

Technology platform backgrounder

Concert has research programs targeting diabetic nephropathy, MRSA infection, pain, BPH, pulmonary, oncology and anti-viral indications.

For further information, please contact Jonathan Montagu, Director of Business Development, jmontagu@concertpharma.com, 781.860.0045 x 206

[ back to top ]